Apollo Health Ventures and Novo led a $15m seed round in Booster Therapeutics.

Apollo Health Ventures, an early stage venture capital firm, and Novo, a global life sciences investor, led a $15m seed round in Booster Therapeutics, a biotechnology company developing a new class of proteasome activator medicines to treat neurodegenerative and other diseases. “Proteasome activation is a truly novel concept because it can potentially transform how we address some of the most multi-factorial diseases. Booster’s deep expertise in proteasome biology means it is well positioned to deliver on first-in-class medicines and expand the protein degradation landscape to more comprehensively address protein dysfunction and impact more disease areas. We’re excited to join efforts with Apollo and the Booster team in order to take this novel therapeutic concept forward for the benefit of patients,” João Ribas, Novo Principal, Seed Investments.